Abstract
Background: Nebivolol is a potent third generation beta-blocking agent indicated for the treatment of hypertension, and is distinguished from other beta blockers by its dual mechanism of action involving high β-1 cardioselectivity and unique nitric-oxide (NO) induced vasodilation. This study aims evaluate the safety and efficacy of Nebivolol (Nebilet) 5mg in the treatment of hypertension among Filipino adult patients. Methods: This is a prospective, open-label, non-interventional study which evaluated the safety of Nebivolol (Nebilet) 5mg in Filipino adult subjects with hypertension, aged 21 to 80 years, in an out-patient setting. Results: A total of 1,154 patients were recruited into the study, 36 (3%) of which had reported adverse events (AEs). Majority of the AEs were due to headaches (18%) and other non-specified events (32%). Most of the adverse events reported were mild to moderate and some were known effects of β- blockers. There were no serious or unsuspected adverse events described during the study. In terms of efficacy, nebivolol reduced blood pressure to less than 140/90 mmHg or a decrease of >10 mm Hg diastolic blood pressure (DBP) in 82% of subjects in the first follow-up visit. At the end of the treatment period, 97% had achieved target blood pressure levels. Conclusions: The study has shown that nebivolol is a safe and effective medication in hypertensive Filipino adult patients.
Highlights
Beta-blocking agents often differ with regards to their selectivity for receptors, lipophilicity, duration of action and intrinsic sympathomimetic activity
Newer beta-blockers were deveNebivolol is a potent cardio-selective beta-blocking agent indicated for the treatment of hypertension, which is distinguished from other selective beta-1-adrenergic antagonists by its peculiar hemodynamic profile
This study showed that nebivolol preserves coronary flow at rest and increased hyperaemic flow velocities despite the reduction of metabolic (O2 consumption) and haemodynamic determinants
Summary
Beta-blocking agents often differ with regards to their selectivity for receptors, lipophilicity, duration of action and intrinsic sympathomimetic activity. Nebivolol was shown to induce a systematic hemodynamic response, consisting in preservation of cardiac output, reduction of peripheral resistance, and improved diastolic dysfunction. This pattern has favorable implications in the treatment of hypertension, but may be clinically relevant in the treatment of heart failure, one of the major complications of hypertension. Nebivolol is a potent third generation beta-blocking agent indicated for the treatment of hypertension, and is distinguished from other beta blockers by its dual mechanism of action involving high β-1 cardioselectivity and unique nitric-oxide (NO) induced vasodilation. This study aims evaluate the safety and efficacy of Nebivolol (Nebilet) 5mg in the treatment of hypertension among Filipino adult patients
Sign-in/Register to view highlights & summary 
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
